Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

被引：19

作者：

Qualls, David ^{[1
]}

Buege, Michael J. ^{[2
]}

Dao, Phuong ^{[2
]}

Caimi, Paolo F. ^{[3
]}

Rutherford, Sarah C. ^{[4
,5
]}

Wehmeyer, Graham ^{[6
]}

Romancik, Jason T. ^{[7
]}

Leslie, Lori A. ^{[8
]}

Merrill, Mwanasha H. ^{[9
]}

Crombie, Jennifer L. ^{[10
]}

Amoozgar, Behzad ^{[11
]}

Kahl, Brad S. ^{[12
]}

Bond, David A. ^{[13
]}

Maddocks, Kami J. ^{[14
]}

Okwali, Michelle ^{[1
]}

Seshan, Venkatraman ^{[15
]}

Salles, Gilles ^{[1
]}

Batlevi, Connie Lee ^{[16
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Pharm, New York, NY USA

[3] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[4] Weill Cornell Med, Meyer Canc Ctr, New York, NY USA

[5] New York Presbyterian Hosp, New York, NY USA

[6] New York Presbyterian Weill Cornell Med Ctr, Dept Med, New York, NY USA

[7] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA

[8] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA USA

[11] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

[12] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA

[13] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH USA

[14] Ohio State Univ, Arthur G James Comprehens Canc Ctr, Dept Internal Med, Wexner Med Ctr, Columbus, OH USA

[15] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA

[16] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, Cellular Therapy Serv, New York, NY USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-167620

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
Qualls, David A.
Lambert, Nicholas
Caimi, Paolo F.
Merrill, Mwanasha
Pullarkat, Priyanka
Godby, Richard C.
Bond, David A.
Wehmeyer, Graham T.
Romancik, Jason
Amoozgar, Behzad
Leslie, Lori
Nastoupil, Loretta J.
Crombie, Jennifer L.
Abramson, Jeremy S.
Khurana, Arushi
Nowakowski, Grzegorz S.
Maddocks, Kami
Rutherford, Sarah C.
Kahl, Brad
Okwali, Michelle
Buege, Michael J.
Seshan, Venkatraman
Batlevi, Connie L.
Salles, Gilles
BLOOD, 2023, 142 (26) : 2327 - 2331
[2] Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria
Ruckdeschel, Anna
Sabrina, Koemm
Topp, Max S.
Greil, Richard
Melchardt, Thomas
Lenz, Georg
Kerkhoff, Andrea
Shumilov, Evgenii
Hess, Georg
Baumgaertner, Marta
Thurner, Lorenz
Kos, Igor Age
Mayer, Stephanie
Ayuk, Francis A.
Krause, Rolf
Herling, Marco
Vucinic, Vladan
Chapuy, Claudia
Illerhaus, Gerald
Knott, Markus
Viardot, Andreas
Grunenberg, Alexander
Dietrich, Sascha
Caille, Leandra
Tometten, Mareike C.
Rosa, Hyunyee
Scholz, Julia
Mueller, Fabian
Prochazka, Katharina
Chapuy, Bjoern
Boeckle, David
von Tresckow, Bastian
Schub, Natalie
Gelbrich, Goetz
Einsele, Hermann
Duell, Johannes
BLOOD, 2023, 142
[3] Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
Nastoupil, Loretta J.
Andersen, Clark
Ayers, Amy
Wang, Yucai
Habermann, Thomas M.
Chihara, Dai
Kahl, Brad S.
Link, Brian K.
Ayyappan, Sabarish
Cohen, Jonathon B.
Martin, Peter
Lossos, Izidore S.
Casulo, Carla
Lin, Ruitao
Li, Ziyi
Larson, Melissa A.
Maurer, Matthew J.
Huynh, Lynn
Gao, Chi
Ramasubramanian, Ramya
Duh, Mei Sheng
Mutebi, Alex
Wang, Tongsheng
Jun, Monika
Wang, Anthony
Kamalakar, Rajesh
Kalsekar, Anupama
Cerhan, James R.
Flowers, Christopher R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S442 - S443
[4] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
Saverno, Kimberly
Savill, Kristin M. Zimmerman
Feinberg, Bruce
Galvin, John
Pathak, Prathamesh
Gordon, Sarah
Amoloja, Theresa
Llorente, Mae
Epperla, Narendranath
Nastoupil, Loretta J.
BLOOD, 2023, 142
[5] Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
Saverno, Kim
Savill, Kristin M. Zimmerman
Feinberg, Bruce
Galvin, John
Pathak, Prathamesh
Amoloja, Theresa
Epperla, Narendranath
Nastoupil, Loretta J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S464 - S464
[6] Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States
Saverno, Kimberly
Nastoupil, Loretta
Feinberg, Bruce
Galvin, John
Pathak, Prathamesh
Amoloja, Theresa
Gentile, Danielle
Asgarisabet, Parisa
Epperla, Narendranath
BLOOD, 2024, 144 : 2375 - 2376
[7] Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axicel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/ R LBCL): A Multicenter Analysis
Vuyyala, Sowjanya
Corraes, Andre De Menezes Silva
Bailey, Megumi
Iqbal, Madiha
Munoz, Javier L.
Hunter, Bradley
Bansal, Radhika
Patel, Krish
Kharfan-Dabaja, Mohamed A.
Rosenthal, Allison C.
Wang, Yucai
Paludo, Jonas
Johnston, Patrick B.
Bennani, N. Nora
Villasboas, J. C. C.
Durani, Urshila
Ansell, Stephen M.
Lin, Yi
Khurana, Arushi
BLOOD, 2023, 142
[8] Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)
Liebers, Nora
Duell, Johannes
Norenberg, Daniel
Kaebisch, Eva
Kerkhoff, Andrea
Acker, Fabian
Fuhrmann, Stephan
Leng, Corinna
Welslau, Manfred
Chemnitz, Jens
Middeke, Jan Moritz
Weber, Thomas
Trappe, Ralf Ulrich
Pfannes, Roald
Liersch, Ruediger
Spoer, Christian
Gebauer, Niklas
Fuxius, Stefan
Caille, Leandra
Pott, Christiane
Koenecke, Christian
Holtick, Udo
Geer, Thomas
Keller, Ulrich
Claus, Rainer
Mougiakakos, Dimitrios
Mayer, Stephanie
Huttmann, Andreas
Trummer, Arne
Wulf, Gerald
Brunnberg, Uta
Bullinger, Lars
Hess, Georg
Mueller-Tidow, Carsten
Glass, Bertram
Lenz, Georg
Dreger, Peter
Dietrich, Sascha
BLOOD, 2020, 136
[9] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
Khurana, Arushi
Bailey, Megumi
Iqbal, Madiha
Bansal, Radhika
Lee, Catherine J.
Hunter, Bradley
Lunning, Matthew A.
Jaglowski, Samantha
Jain, Michael D.
Dahiya, Saurabh
Bachanova, Veronika
Farooq, Umar
Ahmed, Sairah
Hill, Brian T.
Munoz, Javier L.
Patel, Krish
Oluwole, Olalekan O.
Lin, Yi
BLOOD, 2022, 140 : 4657 - 4660
[10] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
Lu, Q.
Huang, H.
Tang, S.
Wang, Y.
Yang, D-H
DRUGS OF TODAY, 2021, 57 (09) : 571 - 580

← 1 2 3 4 5 →